PIR and colorectal carcinoma: The piR-823/PIWIL2 complex mediates STAT3 phosphorylation and the activation of the STAT3/BCL-xl/cyclin D1 pathway, inducing the expression of cyclin-dependent kinase inhibitors and controlling G1 phase regulators Cyclin D1 and CDK4, thus promoting CRC progression [39].